Please assess the completion status of the following clinical trial:

Trial Title: Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adults at high risk of recurrent ischaemic stroke:~1. Age ≥ 50 years~2. Within 48 hours of ictus (24-48 hours if thrombolysed)~3. TIA with limb weakness and/or dysphasia lasting between 10 minutes and \< 24 hours with no residual symptoms and presenting with any of the following~   * ABCD2 score \> 4, or~  * Crescendo TIA or~  * Already on dual antiplatelet therapy~   Note: Neuroimaging is not necessary for transient ischaemic attack. Crescendo TIA is \> 1 TIA in one week and the onset time of last TIA is taken as time of ictus.~4. Ischaemic non cardioembolic stroke presenting with any of the following~   * Ongoing limb weakness and/or dysphasia of more than one hour duration~  * Resolved limb weakness of more than one hour duration with ongoing facial weakness~  * Ongoing isolated hemianopia of more than 1 hour duration with positive neuroimaging evidence to support the index event (e.g. ischaemic stroke in occipital lobe)~  * Resolved limb weakness and/or dysphasia between 24-48 hours after index event onset~   Note: Neuroimaging is essential for ischaemic stroke to exclude intracranial haemorrhage and/or non stroke diagnosis~5. Informed consent from participant. If the participant is unable to give meaningful consent e.g. due to dysphasia, confusion, or reduced conscious level, proxy consent may be obtained from a relative, carer or legal representative.~Exclusion Criteria:~1. Age \< 50~2. Isolated sensory symptoms or vertigo/dizziness or facial weakness~3. Isolated hemianopia without positive neuroimaging evidence~4. Intracranial haemorrhage~5. Baseline neuroimaging showing parenchymal haemorrhagic transformation (PH I/II) of infarct, subarachnoid haemorrhage or other non ischaemic cause for symptoms~6. Presumed cardioembolic stroke (e.g. history or current AF, myocardial infarction within 3 months)~7. Participants with contraindications to, or intolerance of, aspirin, clopidogrel or dipyridamole.~8. Participants with definite need for treatment with aspirin, clopidogrel or dipyridamole individually or in combination (e.g. aspirin and clopidogrel for recent MI/acute coronary syndrome)~9. Participant has taken clopidogrel or dipyridamole after the index event but prior to randomisation (aspirin is allowed between ictus onset and randomisation)~10. Definite need for full dose oral (e.g. warfarin, dabigatran) or medium to high dose parenteral (e.g. heparin) anti-coagulation. NB Low dose heparin for DVT prophylaxis is allowed~11. Definite need for glycoprotein IIb-IIIa inhibitors~12. Received thrombolysis within the last 24 hours~13. No enteral access~14. Pre-morbid dependency (mRS \> 2).~15. Severe high BP (BP \> 185/110 mmHg).~16. Haemoglobin less than 10g/dL~17. Platelet count more than 600 x 109 /L or less than 100 x 109 /L~18. White cell count more than 30 x 109 /L or less than 3.5 x 109 /L~19. Major bleeding within 1 year (e.g. peptic ulcer, intracerebral haemorrhage).~20. Planned surgery during 3 month follow-up (e.g. carotid endarterectomy)~21. Concomitant STEMI or NSTEMI.~22. Stroke secondary to a procedure (e.g. carotid or coronary intervention)~23. Coma (GCS \< 8)~24. Non-stroke life expectancy \< 6 months~25. Dementia~26. Participation in another drug or devices trial concurrently or within 30 days. (participants may take part in observational studies or non-drug or devices trials)~27. Geographical or other factors that may interfere with follow-up e.g. no fixed address or telephone contact number, not registered with a GP, or overseas visitor.~28. Females of childbearing potential, pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intensive antiplatelet therapy (Type: ACTIVE_COMPARATOR): Participants in the intensive antiplatelet group will receive Aspirin+Dipyridamole+Clopidogrel triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
- Guideline antiplatelet therapy (Type: NO_INTERVENTION): This may be one or two antiplatelet drugs, as per standard treatment. Clopidogrel or aspirin and dipyridamole.

Based on this trial design, predict the completion outcome and termination type (if applicable).